Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
NCT02238522
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Conditions
Lymphoproliferative Malignancies
Acute Myeloid Leukemia
Interventions
DRUG:
ZEN003365
Sponsor
Zenith Epigenetics